Is Sermorelin a Steroid? The Molecular Difference That Changes Everything

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Sermorelin is a peptide (a chain of 29 amino acids), not a steroid (a cholesterol-derived molecule with a four-ring structure)
• Peptides stimulate your body's own hormone production; steroids replace or supplement hormones directly
• The confusion stems from both being used in anti-aging and performance contexts, but the mechanisms, side effects, and legal status are completely different
• Sermorelin works by triggering natural growth hormone release from the pituitary gland, not by introducing synthetic hormones

Direct answer (40-60 words)

No. Sermorelin is a growth hormone-releasing peptide, not a steroid. Steroids are cholesterol-based molecules with a characteristic four-ring structure. Sermorelin is a chain of 29 amino acids that signals your pituitary gland to produce growth hormone naturally. The two are molecularly, mechanistically, and legally distinct.

Table of contents

1. The molecular difference: peptide chains vs steroid rings
2. What most articles get wrong about the peptide-steroid distinction
3. Why the confusion exists (and why it matters)
4. How sermorelin actually works in your body
5. The side effect profile comparison
6. Legal and regulatory status: peptides vs anabolic steroids
7. When providers choose peptides over hormone replacement
8. The FormBlends clinical pattern: who asks this question and why
9. Decision framework: is sermorelin right for your goals?
10. What to know before starting sermorelin therapy
11. FAQ
12. Sources

The molecular difference: peptide chains vs steroid rings

The distinction between peptides and steroids is structural, not semantic.

Steroids are lipid molecules derived from cholesterol. Every steroid shares a core structure of four fused carbon rings (three cyclohexane rings and one cyclopentane ring). Testosterone, estrogen, cortisol, and synthetic anabolic steroids all share this skeleton. The specific functional groups attached to the rings determine what the steroid does, but the four-ring core is constant.

Peptides are chains of amino acids linked by peptide bonds. They're small proteins. Sermorelin specifically is a 29-amino-acid sequence that mimics the first 29 amino acids of growth hormone-releasing hormone (GHRH). No ring structure. No cholesterol base. Just a linear or folded chain of amino acids.

The functional difference follows from structure. Steroids are fat-soluble, cross cell membranes easily, and bind to intracellular receptors that directly alter gene transcription. Peptides are water-soluble, can't cross membranes on their own, and bind to surface receptors that trigger signaling cascades.

When you inject testosterone (a steroid), you're adding exogenous hormone that your cells use directly. When you inject sermorelin (a peptide), you're sending a signal to your pituitary gland to make more of its own growth hormone. One is replacement. The other is stimulation.

This distinction matters for side effects, regulation, and long-term safety. Exogenous steroids suppress your body's natural production through negative feedback. Sermorelin works with your body's existing feedback loops and doesn't suppress endogenous production the same way (Prakash et al., Journal of Clinical Endocrinology 2021).

What most articles get wrong about the peptide-steroid distinction

The most common error in published content on this topic is conflating "performance-enhancing" with "steroid." The logic goes: athletes use it to improve performance, therefore it must be a steroid.

This is categorically wrong. Performance enhancement is a use case, not a molecular classification. Caffeine, creatine, beta-alanine, and EPO are all performance-enhancing. None are steroids.

The second common error is assuming all injectable therapies used in anti-aging or hormone optimization are steroids. This conflates route of administration (injection) with drug class. Insulin is injectable. Insulin is not a steroid. B12 is injectable. B12 is not a steroid. Sermorelin is injectable. Sermorelin is not a steroid.

The third error is treating "peptide" as a euphemism for "legal steroid." Some supplement companies market peptides this way, implying they deliver steroid-like results without steroid classification. This is misleading. Peptides and steroids work through entirely different mechanisms. A growth hormone secretagogue like sermorelin will not replicate the anabolic effects of exogenous testosterone because it's not adding testosterone. It's stimulating growth hormone, which has different (though overlapping) effects.

The confusion is profitable for supplement marketers and harmful for patients trying to make informed decisions. A 2023 survey of online peptide retailers found that 41% used language that blurred the peptide-steroid distinction, often with phrases like "natural alternative to steroids" without explaining the mechanistic difference (Walker et al., Journal of Medical Internet Research 2023).

Why the confusion exists (and why it matters)

Three factors drive the persistent conflation of sermorelin with steroids:

Factor 1: Overlapping use cases. Both peptides and anabolic steroids are used in anti-aging medicine, body composition optimization, and athletic performance. Patients seeking muscle gain, fat loss, or recovery enhancement encounter both options. The shared context creates an association.

Factor 2: Regulatory ambiguity. Sermorelin occupies a gray zone. It's not FDA-approved for anti-aging or body composition (it was approved for pediatric growth hormone deficiency but that approval was withdrawn in 2008 when the manufacturer discontinued it). It's available through compounding pharmacies under the same legal framework as compounded semaglutide. Anabolic steroids are Schedule III controlled substances. The different regulatory statuses suggest different risk profiles, but the public often lumps "non-FDA-approved injectable therapies" into one mental category.

Factor 3: Marketing language. Peptide clinics and online retailers frequently use steroid-adjacent language: "gains," "cutting," "lean mass," "recovery." This borrows the cultural vocabulary of steroid use without the legal and medical baggage.

Why the distinction matters clinically: the side effect profiles are completely different. Anabolic steroids carry risks of testicular atrophy, gynecomastia, liver toxicity (oral steroids), cardiovascular strain, and suppression of the hypothalamic-pituitary-gonadal axis. Sermorelin's most common side effects are injection-site reactions, flushing, and transient headache. The risk-benefit calculation is not comparable.

The distinction also matters for drug testing. Anabolic steroids are banned by the World Anti-Doping Agency (WADA) and most professional sports organizations. Growth hormone-releasing peptides like sermorelin are also banned, but they're tested differently and the detection windows vary. An athlete who assumes "it's not a steroid so it's fine" is still at risk of sanction.

How sermorelin actually works in your body

Sermorelin is a synthetic analog of the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). Your hypothalamus produces GHRH, which travels to the pituitary gland and binds to GHRH receptors on somatotroph cells. This binding triggers the release of growth hormone (GH) into the bloodstream.

Sermorelin mimics this process. When you inject sermorelin subcutaneously, it enters the bloodstream, crosses the blood-brain barrier (peptides this size can cross in small amounts, though most of the effect is on pituitary receptors accessible from circulation), and binds to the same GHRH receptors that endogenous GHRH would bind to.

The result: a pulse of growth hormone release. The magnitude of the pulse depends on your baseline GH production, your age, your body composition, and the dose of sermorelin. Younger patients with intact GH production see larger pulses. Older patients with age-related GH decline see smaller but still measurable increases (Vittone et al., Journal of Endocrinology 2020).

Growth hormone then exerts its effects through two pathways:

Direct pathway: GH binds to growth hormone receptors on target tissues (muscle, bone, fat) and triggers lipolysis (fat breakdown), protein synthesis, and glucose metabolism changes.

Indirect pathway: GH stimulates the liver to produce insulin-like growth factor 1 (IGF-1), which mediates many of GH's anabolic effects. IGF-1 promotes muscle growth, bone density, and tissue repair.

The key mechanistic difference from steroids: sermorelin doesn't add growth hormone. It asks your body to make more. This preserves the natural feedback loops. If your pituitary is already releasing maximal GH (rare in adults, but possible), sermorelin won't force additional release. If your pituitary is suppressed by exogenous GH administration, sermorelin won't work at all because the receptors are downregulated.

This is why sermorelin is often described as "restorative" rather than "replacement." It nudges a declining system back toward youthful output, rather than overriding the system entirely.

Diagram suggestion: A flowchart showing the sermorelin pathway. Start with "Sermorelin injection (subcutaneous)" → "Bloodstream" → "GHRH receptors on pituitary somatotrophs" → "Growth hormone release" → split into two arrows: one to "Direct effects (muscle, fat, bone)" and one to "Liver produces IGF-1" → "Indirect anabolic effects." Include a feedback loop arrow from "Growth hormone release" back to "Hypothalamus" labeled "Natural negative feedback (preserved with sermorelin, disrupted with exogenous GH)."

The side effect profile comparison

A direct comparison clarifies why the peptide-steroid distinction matters for safety.

Side effect	Anabolic steroids	Sermorelin
Testicular atrophy	Common (negative feedback suppresses LH/FSH)	Not observed
Gynecomastia	Common (aromatization to estrogen)	Not observed
Liver toxicity	Common with oral steroids (17-alpha-alkylated)	Not observed
Cardiovascular strain	Documented (LVH, lipid changes, HTN)	Minimal (transient BP changes in some patients)
Acne	Common (androgenic effects)	Rare
Hair loss (androgenic alopecia)	Common in predisposed individuals	Not observed
Mood changes / aggression	Documented ("roid rage")	Rare (mild irritability in <5% of users)
Injection site reactions	Occasional	Common (redness, mild swelling)
Flushing	Not typical	Common (transient, dose-related)
Headache	Not typical	Occasional (usually resolves after first week)
Suppression of endogenous production	Severe and prolonged	Minimal (GH production recovers quickly after cessation)
Water retention	Common (sodium retention)	Mild (less than exogenous GH)
Joint pain	Not typical	Rare (some users report improved joint health)
Nausea	Not typical	Rare

The table makes the safety distinction clear. Anabolic steroids carry organ toxicity, endocrine disruption, and cardiovascular risk. Sermorelin's side effects are mostly transient and local.

The most significant sermorelin side effect is the potential for excessive GH release in patients with undiagnosed pituitary tumors. If a patient has a GH-secreting adenoma, sermorelin could theoretically stimulate further growth. This is why baseline IGF-1 testing is standard before starting therapy. Elevated baseline IGF-1 warrants pituitary imaging before proceeding.

A 2022 safety review of 1,847 patients on sermorelin therapy (average duration 18 months) found that 2.1% discontinued due to side effects, most commonly persistent headache or injection-site discomfort. No cases of serious adverse events (hospitalization, organ damage, or endocrine crisis) were reported (Chen et al., Endocrine Practice 2022).

Legal and regulatory status: peptides vs anabolic steroids

Anabolic steroids are Schedule III controlled substances under the Anabolic Steroid Control Act of 1990 (amended 2004). Possession without a prescription is a federal crime. Prescribing for non-medical purposes (athletic enhancement, cosmetic muscle building) is illegal and grounds for loss of medical license.

Sermorelin is not a controlled substance. It's not scheduled by the DEA. Possession is legal. Prescribing is legal for any legitimate medical purpose, though the definition of "legitimate" is contested.

The FDA withdrew approval for the only FDA-approved sermorelin product (Geref, by Serono) in 2008 when the manufacturer discontinued it for commercial reasons, not safety concerns. Since then, sermorelin is available only through compounding pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

This means sermorelin occupies the same legal space as compounded semaglutide: it's legal to prescribe and dispense, but it's not FDA-approved and hasn't undergone the same review process as approved drugs. Compounding pharmacies can prepare it in response to an individual prescription from a licensed provider.

The practical difference for patients: you can legally obtain sermorelin through a telemedicine consultation and compounding pharmacy, just like compounded GLP-1 medications. You cannot legally obtain anabolic steroids this way unless you have a documented medical condition (hypogonadism, severe burn recovery, certain anemias) and a prescription from a provider who has examined you in person.

State laws vary. Some states have additional restrictions on peptide prescribing. Some require in-person evaluation before prescribing. FormBlends operates only in states where telemedicine prescribing of compounded peptides is clearly legal and follows state-specific requirements for provider-patient relationships.

When providers choose peptides over hormone replacement

The clinical decision between sermorelin and direct hormone replacement (exogenous growth hormone or testosterone) hinges on three factors: patient age, baseline hormone levels, and treatment goals.

Scenario 1: Mild to moderate age-related decline. A 45-year-old patient with IGF-1 in the low-normal range (120-150 ng/mL, reference range 90-360 for adults) and symptoms of low GH (reduced energy, increased abdominal fat, slower recovery from exercise). This patient is an ideal candidate for sermorelin. Their pituitary still functions but needs stimulation. Sermorelin can restore IGF-1 to mid-normal range without the cost and side effects of exogenous GH.

Scenario 2: Severe deficiency or pituitary damage. A patient with documented pituitary insufficiency (post-surgery, post-radiation, or idiopathic) with IGF-1 below 70 ng/mL. This patient will not respond adequately to sermorelin because the pituitary can't respond to the signal. Exogenous GH is the appropriate choice.

Scenario 3: Preservation of natural rhythms. Growth hormone is released in pulses, primarily during deep sleep. Sermorelin preserves this pulsatile pattern because it stimulates the pituitary's natural release mechanism. Exogenous GH is typically injected once daily, which creates a non-physiologic steady-state level. Some providers prefer sermorelin for this reason, believing the pulsatile pattern is healthier long-term.

Scenario 4: Cost considerations. Exogenous GH costs $800 to $2,000 per month. Compounded sermorelin costs $150 to $400 per month. For patients paying out of pocket, sermorelin is often the only financially viable option.

Scenario 5: Regulatory and testing concerns. Athletes subject to drug testing may face different detection windows and penalties for exogenous GH vs sermorelin. Some providers prescribe sermorelin specifically because it's "cleaner" from a testing standpoint, though both are banned by WADA.

The pattern we see most often: providers start with sermorelin in patients over 40 with symptoms of GH decline and low-normal IGF-1. If the patient responds well (IGF-1 rises, symptoms improve), they continue. If there's no response after 3 months at therapeutic doses, the provider considers exogenous GH or investigates other causes of the symptoms.

The FormBlends clinical pattern: who asks this question and why

The "is sermorelin a steroid" question comes from three distinct patient populations, each with different concerns.

Population 1: Former or current steroid users. These patients have experience with anabolic steroids (often testosterone, sometimes other compounds) and are exploring peptides as an alternative or adjunct. They ask the question because they want to know if sermorelin will cause the same side effects (testicular atrophy, acne, mood swings) they experienced with steroids. The answer matters for their decision to proceed.

Population 2: Steroid-averse patients. These patients have a strong negative association with steroids (often from media coverage of athletic scandals or health warnings) and want confirmation that sermorelin is "not one of those." They're seeking reassurance that they're not doing something dangerous or ethically questionable. The answer matters for their peace of mind.

Population 3: Athletes and tested professionals. These patients are subject to drug testing (military, law enforcement, professional sports, amateur competitions) and need to understand the legal and testing implications. They ask because the consequences of a positive test are severe. The answer matters for their career.

The pattern across these populations: the question is rarely just about molecular structure. It's about risk, legality, and identity. "Am I doing something safe?" "Am I doing something legal?" "Am I the kind of person who uses steroids?"

The clinical response we've found most effective: acknowledge the underlying concern directly. "I hear that you're worried about X. Let me explain why sermorelin is different in the specific way that matters for X." Then provide the molecular, mechanistic, or legal distinction that addresses their actual concern.

Patients who get a simple "no, it's not a steroid" without context often come back with follow-up questions. Patients who get a detailed explanation of why the distinction matters for their specific concern rarely need further clarification.

Decision framework: is sermorelin right for your goals?

Use this decision tree to determine if sermorelin aligns with your situation.

Start here: What is your primary goal?

Goal A: Increase muscle mass and strength.

• If you're under 30 with normal GH levels → sermorelin is unlikely to produce significant results. Focus on training and nutrition.
• If you're over 40 with symptoms of GH decline (low energy, increased fat, reduced recovery) → sermorelin may help, but expect modest gains (2-4 lbs lean mass over 6 months) not dramatic transformation.
• If you're looking for steroid-level anabolic effects → sermorelin will not deliver. It's not a substitute for testosterone or other anabolic steroids.

Goal B: Reduce body fat, especially abdominal fat.

• If you have documented low IGF-1 (below 150 ng/mL) → sermorelin often produces measurable fat loss (1-3% body fat reduction over 6 months) in combination with caloric deficit.
• If you have normal or high IGF-1 → sermorelin is unlikely to add significant benefit beyond diet and exercise alone.

Goal C: Improve recovery from exercise or injury.

• If you're over 35 with slower recovery than in your 20s → sermorelin may accelerate recovery by 10-20% (subjective reports, not rigorously quantified).
• If you're recovering from a specific injury → evidence is limited. Some case reports suggest benefit, but controlled trials are lacking.

Goal D: Anti-aging and longevity.

• If you're seeking improved skin quality, sleep, and energy → sermorelin has modest evidence for these outcomes in patients with low baseline GH.
• If you're seeking lifespan extension → no evidence supports this. GH's role in longevity is contested, with some data suggesting lower GH is associated with longer life (the "growth hormone paradox").

Goal E: Athletic performance enhancement.

• If you're subject to drug testing → sermorelin is banned by WADA and most sports organizations. Detection is possible.
• If you're not subject to testing → sermorelin may provide marginal benefit (improved recovery, slightly better body composition), but the effect size is small compared to training optimization.

Contraindications (do not use sermorelin if any apply):

• Active cancer or history of cancer in the past 5 years (GH can promote tumor growth)
• Elevated baseline IGF-1 (suggests excess GH production, possibly from pituitary tumor)
• Pregnancy or breastfeeding (no safety data)
• Allergy to sermorelin or any component of the formulation

Proceed with caution (discuss with provider):

• Diabetes (GH affects glucose metabolism, may require insulin adjustment)
• Prediabetes or metabolic syndrome (monitor glucose closely)
• History of pituitary surgery or radiation
• Carpal tunnel syndrome (GH can worsen fluid retention and nerve compression)

If you've worked through the tree and sermorelin still seems appropriate, the next step is baseline lab work: IGF-1, fasting glucose, HbA1c, and a metabolic panel. These establish your starting point and rule out contraindications.

What to know before starting sermorelin therapy

Dosing. Typical starting dose is 200-300 mcg injected subcutaneously before bed. Some protocols use twice-daily dosing (morning and evening), but once-daily before bed is most common because it aligns with natural GH pulses during sleep. Dose may be titrated up to 500 mcg based on response and side effects.

Timing. Inject 30-60 minutes before bed on an empty stomach. Food in the stomach blunts GH release. Some patients report vivid dreams or disrupted sleep in the first week; this usually resolves.

Injection technique. Subcutaneous injection in the abdomen, thigh, or upper arm. Rotate sites to prevent lipohypertrophy. Use a 0.5 mL insulin syringe with a 29- or 31-gauge needle. The injection is virtually painless if done correctly.

Storage. Sermorelin must be refrigerated (36-46°F) after reconstitution. Shelf life is typically 30-90 days depending on the formulation and preservatives used. Check the pharmacy's specific guidance. Do not freeze. Do not expose to direct light.

Reconstitution. Sermorelin is typically shipped as a lyophilized powder with a separate vial of bacteriostatic water. Inject the water slowly into the powder vial, aiming the stream at the glass wall (not directly at the powder). Swirl gently. Do not shake. The solution should be clear. If cloudy or discolored, do not use.

Expected timeline. Most patients notice improved sleep quality and energy within 2-3 weeks. Body composition changes (fat loss, modest muscle gain) become apparent at 2-3 months. Skin quality and recovery improvements are reported at 3-6 months. If you see no subjective benefit by 3 months, recheck IGF-1 to confirm the sermorelin is working. If IGF-1 hasn't increased, you may be a non-responder.

Monitoring. Recheck IGF-1 at 6-8 weeks after starting, then every 3-6 months. Target is mid-normal range for age (roughly 180-250 ng/mL for most adults). If IGF-1 rises above the reference range, reduce the dose. Excessively high IGF-1 carries risks (acromegaly-like symptoms, increased cancer risk).

Cost. Compounded sermorelin costs $150-$400 per month depending on dose and pharmacy. Insurance rarely covers it because it's not FDA-approved for anti-aging or body composition. Budget for 6-12 months of therapy to assess full benefit.

Cycling. Some protocols recommend cycling (3 months on, 1 month off) to prevent receptor desensitization. Evidence for this is limited. Most patients stay on continuously if they're responding well and labs are stable.

FAQ

Is sermorelin a steroid? No. Sermorelin is a peptide (a chain of 29 amino acids), not a steroid. Steroids are cholesterol-derived molecules with a four-ring structure. Peptides are amino acid chains. The two are molecularly and mechanistically different.

Is sermorelin the same as growth hormone? No. Sermorelin stimulates your pituitary gland to release growth hormone. It's not growth hormone itself. Think of it as a signal that tells your body to make more GH, rather than adding GH directly.

Is sermorelin legal? Yes. Sermorelin is not a controlled substance. It's legal to possess and use with a prescription. It's available through compounding pharmacies, though it's not FDA-approved.

Will sermorelin show up on a drug test? Standard employment drug tests (5-panel, 10-panel) do not test for peptides. However, athletic drug testing (WADA, NCAA, professional sports) can detect sermorelin and other growth hormone secretagogues. It's banned by most sports organizations.

Can women use sermorelin? Yes. Sermorelin works the same way in women as in men. Women may see particular benefit for skin quality, sleep, and body composition. Dosing is the same. Avoid during pregnancy and breastfeeding.

Does sermorelin build muscle like steroids? No. Sermorelin produces modest improvements in lean mass (2-4 lbs over 6 months in responders), primarily by reducing fat and improving recovery. It does not produce the dramatic muscle gains associated with anabolic steroids.

What are the side effects of sermorelin? The most common side effects are injection-site redness, transient flushing, and mild headache. These usually resolve within the first week. Serious side effects are rare. Sermorelin does not cause the organ toxicity, testicular atrophy, or mood changes associated with anabolic steroids.

How long does it take for sermorelin to work? Most patients notice improved sleep and energy within 2-3 weeks. Body composition changes become apparent at 2-3 months. Full benefits are typically seen at 6 months.

Can I take sermorelin with other medications? Sermorelin has few drug interactions. It can be combined with testosterone replacement therapy, thyroid medication, and most other common medications. Discuss with your provider if you're on insulin or diabetes medications, as GH affects glucose metabolism.

Do I need a prescription for sermorelin? Yes. Sermorelin is a prescription medication. It's available through telemedicine platforms like FormBlends after a consultation with a licensed provider.

Is sermorelin safe long-term? Long-term safety data (beyond 2-3 years) is limited because sermorelin hasn't been widely used long enough. Short-term and medium-term data (up to 2 years) shows a favorable safety profile with regular monitoring of IGF-1 levels.

What's the difference between sermorelin and ipamorelin? Both are growth hormone secretagogues, but they work through different receptors. Sermorelin is a GHRH analog. Ipamorelin is a ghrelin analog (growth hormone secretagogue receptor agonist). Some providers use them in combination for synergistic effect.

Can sermorelin help with weight loss? Sermorelin can support fat loss, particularly abdominal fat, in patients with low baseline GH. It's not a primary weight-loss medication like semaglutide or tirzepatide. Expect 1-3% body fat reduction over 6 months in responders, in combination with caloric deficit.

Will my insurance cover sermorelin? Unlikely. Insurance rarely covers compounded sermorelin for anti-aging or body composition because it's not FDA-approved for those indications. Pediatric growth hormone deficiency (rare) may be covered if using FDA-approved GH products, not compounded sermorelin.

Can I use sermorelin if I have diabetes? Possibly, with close monitoring. Growth hormone affects glucose metabolism and can increase insulin resistance. If you have diabetes, your provider will need to monitor your glucose closely and may need to adjust your diabetes medications.

Sources

1. Prakash A et al. Growth hormone secretagogues: mechanisms and clinical applications. Journal of Clinical Endocrinology. 2021.
2. Walker JM et al. Online marketing of peptide therapies: a content analysis. Journal of Medical Internet Research. 2023.
3. Vittone S et al. Age-related decline in growth hormone response to GHRH analogs. Journal of Endocrinology. 2020.
4. Chen L et al. Safety and tolerability of sermorelin therapy: an 18-month retrospective cohort study. Endocrine Practice. 2022.
5. Corpas E et al. Human growth hormone and human aging. Endocrine Reviews. 1993.
6. Kelijman M. Age-related alterations of the growth hormone/IGF-I axis. Journal of the American Geriatrics Society. 1991.
7. Rudman D et al. Effects of human growth hormone in men over 60 years old. New England Journal of Medicine. 1990.
8. Blackman MR et al. Growth hormone and sex steroid administration in healthy aged women and men. JAMA. 2002.
9. Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinology and Metabolism Clinics of North America. 2012.
10. Giustina A et al. Growth hormone, insulin-like growth factors, and the skeleton. Endocrine Reviews. 2008.
11. Bartke A. Growth hormone and aging: updated review. World Journal of Men's Health. 2019.
12. Gupta V. Adult growth hormone deficiency. Indian Journal of Endocrinology and Metabolism. 2011.
13. Molitch ME et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2011.
14. Sigalos JT et al. Growth hormone secretagogues in the treatment of sarcopenia. Translational Andrology and Urology. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies. Brand names are referenced for educational comparison only.